DK1404852T3 - Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren - Google Patents

Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren

Info

Publication number
DK1404852T3
DK1404852T3 DK03732369T DK03732369T DK1404852T3 DK 1404852 T3 DK1404852 T3 DK 1404852T3 DK 03732369 T DK03732369 T DK 03732369T DK 03732369 T DK03732369 T DK 03732369T DK 1404852 T3 DK1404852 T3 DK 1404852T3
Authority
DK
Denmark
Prior art keywords
expression
vaccinia virus
coccyx
genes
modified vaccinia
Prior art date
Application number
DK03732369T
Other languages
English (en)
Inventor
Paul Howley
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK200201813A external-priority patent/DK200201813A/da
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1404852T3 publication Critical patent/DK1404852T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03732369T 2002-05-16 2003-05-14 Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren DK1404852T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200754 2002-05-16
DK200201813A DK200201813A (da) 2002-11-25 2002-11-25 Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper

Publications (1)

Publication Number Publication Date
DK1404852T3 true DK1404852T3 (da) 2006-05-08

Family

ID=29551229

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03732369T DK1404852T3 (da) 2002-05-16 2003-05-14 Ekspression af gener i modificeret vacciniavirus Ankara ved anvendelse af kokoppe-ATI-promotoren

Country Status (21)

Country Link
US (1) US20060029619A1 (da)
EP (1) EP1404852B1 (da)
JP (1) JP2005525821A (da)
KR (1) KR20040108804A (da)
CN (1) CN1289682C (da)
AT (1) ATE313641T1 (da)
AU (1) AU2003240243B2 (da)
BR (1) BR0310020A (da)
CA (1) CA2481783A1 (da)
DE (1) DE60302848T2 (da)
DK (1) DK1404852T3 (da)
EA (1) EA009525B1 (da)
ES (1) ES2256747T3 (da)
HK (1) HK1076835A1 (da)
IL (1) IL164179A0 (da)
MX (1) MXPA04011034A (da)
NO (1) NO20045315L (da)
NZ (1) NZ536500A (da)
PL (1) PL372091A1 (da)
SI (1) SI1404852T1 (da)
WO (1) WO2003097844A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
DK1434858T4 (da) * 2002-09-05 2019-04-01 Bavarian Nordic As Fremgangsmåde til amplifikation af et poxvirus under serumfri betingelser
DE602004027767D1 (de) 2003-11-24 2010-07-29 Bavarian Nordic As Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US7972605B2 (en) * 2006-09-08 2011-07-05 Duke University Modified vaccinia ankara virus vaccine
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
AU2010305030A1 (en) 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
JP7554423B2 (ja) 2019-03-14 2024-09-20 公益財団法人東京都医学総合研究所 デングウイルスワクチン

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
JPH01218590A (ja) * 1988-02-29 1989-08-31 Toa Nenryo Kogyo Kk 組換ワクチニアウイルスを用いたリンダペスト(牛疫)ウイルスワクチン
JP3044062B2 (ja) * 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5452364A (en) * 1993-12-07 1995-09-19 Bonham; Douglas M. System and method for monitoring wildlife
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0951555A2 (en) * 1996-09-24 1999-10-27 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) * 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体

Also Published As

Publication number Publication date
US20060029619A1 (en) 2006-02-09
DE60302848D1 (de) 2006-01-26
AU2003240243A1 (en) 2003-12-02
IL164179A0 (en) 2005-12-18
NO20045315L (no) 2004-12-03
ES2256747T3 (es) 2006-07-16
SI1404852T1 (sl) 2006-04-30
EA200401505A1 (ru) 2005-04-28
EA009525B1 (ru) 2008-02-28
JP2005525821A (ja) 2005-09-02
CN1289682C (zh) 2006-12-13
CN1653181A (zh) 2005-08-10
NZ536500A (en) 2008-01-31
MXPA04011034A (es) 2005-02-14
WO2003097844A1 (en) 2003-11-27
HK1076835A1 (en) 2006-01-27
KR20040108804A (ko) 2004-12-24
DE60302848T2 (de) 2006-08-31
BR0310020A (pt) 2005-02-15
PL372091A1 (en) 2005-07-11
CA2481783A1 (en) 2003-11-27
EP1404852A1 (en) 2004-04-07
AU2003240243B2 (en) 2009-01-22
ATE313641T1 (de) 2006-01-15
EP1404852B1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
NO20053125D0 (no) Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.
ATE465750T1 (de) Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell- immunantwort gegen antigen
IL174653A0 (en) Promoters for expression in modified vaccinia virus ankara
HUE037330T2 (hu) rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
RS50977B (sr) Replikaciono defektni rnk-virusi kao vakcine
WO2003047617A3 (en) Vaccine
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
BRPI0516576B8 (pt) vetores quiméricos
AU2003219057A8 (en) Recombinant drug-sensitive vaccinia virus as smallpox vaccine
WO2002086059A3 (en) Recombinant vaccinia viral vectors
JP2009232836A5 (da)
DE50312368D1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
BR0012556A (pt) Genes e vacinas de ehrlichia canis
DK1430134T3 (da) HDV-nukleinsyremolekyler, fragmenter og anvendelser deraf
NZ595176A (en) Influenza Viruses Able to Infect Canids, Uses Thereof
ATE547530T1 (de) Rekombinante vektoren auf der grundlage des modifizierten vacciniavirus ankara (mva) als impfstoffe gegen leishmaniase